glp-1 news Prescriptions Quadruple Since 2021 Alongside Decline In Obesity Fmr. FDA Commissioner weighs in
Description
doi:10.1176/appi.ajp.20230012CrossRefGoogle ScholarPubMed McElroy, SL, Keck, PE
Boehringer Ingelheim GmbH terminated its second metabolic dysfunction-associated steatohepatitis (MASH) alliance on March 6, ending an $870 million license agreement inked with Yuhan Corp
This shift has encouraged healthcare providers to prescribe anti-obesity medications more readily, particularly for patients with obesity-related comorbidities
These include decreased urination or dark-colored urine, dizziness or lightheadedness, extreme thirst and dry mouth, or unusual tiredness and weakness
